Abhijit Trailokya
Sunil Chaudhry
- Senior General Manager Indoco Remedies, Mumbai Maharashtra India
- Director Solutions and Consultant, Edenwell Therapeutics Private Limited Mumbai Maharashtra India
Abstract
Dipeptidyl peptidase-4 inhibitors (DPP-4Is) have become essential in managing type 2 diabetes mellitus (T2DM) due to their ability to enhance incretin hormone activity, which promotes insulin secretion and inhibits glucagon release. These agents effectively lower HbA1c levels by 0.5-1.0%, are weight-neutral, and have a low risk of hypoglycemia, making them suitable for a broad patient population, including the elderly. The antidiabetic market in India is vast. Gliptin as group row at rate of 40%, the market size is INR 1800 Crores. Common DPP-4 inhibitors include alogliptin, sitagliptin, saxagliptin, teneligliptin and linagliptin, each with unique pharmacokinetic profiles. While generally well-tolerated, rare adverse effects such as pancreatitis and joint pain have been reported. Gliptins in terms of efficacy are non-inferior to sulfonylurea and metformin and are well tolerated.DPP-4 inhibitors are administered orally, once daily (except vildagliptin), before or after meals. Gliptins result in modest improvement in HbA1c, with a reduction of around 0.5–1.0% when used as monotherapy and around 0.6–1.1% when used in combination with metformin, depending on the agent, dose of therapy and starting HbA1c. Recent developments highlight the increasing use of DPP-4 inhibitors in combination therapies with other antidiabetic agents, such as SGLT2 inhibitors, to optimize glycemic control and provide additional benefits like weight loss and cardioprotection (except saxagliptin).
Keywords: DPP4 inhibitors, type 2 diabetes mellitus, Cardiovascular Events, glycosylated haemoglobin, CD26.
[This article belongs to Research & Reviews: A Journal of Pharmacology(rrjop)]
References
1. Xiao-Wu Chen, Zhi-Xu He, Zhi-Wei Zhou et.al. Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus. Clinical and Experimental Pharmacology and Physiology (2015) 42, 999–1024.
2. Yin, R.; Xu, Y.;Wang, X.; Yang, L.; Zhao, D. Role of Dipeptidyl Peptidase 4 Inhibitors in Antidiabetic Treatment. Molecules 2022, 27, 3055. https://doi.org/10.3390/ molecules27103055.
3. Gallwitz B (2019) Clinical Use of DPP-4 Inhibitors. Front. Endocrinol. 10:389. doi: 10.3389/fendo.2019.00389.
4. Ahrén B. DPP-4 Inhibition and the Path to Clinical Proof. Front Endocrinol (Lausanne). 2019 Jun 19;10:376. doi: 10.3389/fendo.2019.00376.
5. Jixin Zhong, Quan Gong, Aditya Goud at.el. Recent Advances in Dipeptidyl-Peptidase-4 Inhibition Therapy: Lessons from the Bench and Clinical Trials. Journal of Diabetes Research Volume 2015, Article ID 606031, 14 pages http://dx.doi.org/10.1155/2015/606031
6. Capuano A, Sportiello L, Maiorino MI, Rossi F, Giugliano D, Esposito K. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy–focus on alogliptin. Drug Des Devel Ther. 2013 Sep 17;7:989-1001. doi: 10.2147/DDDT.S37647.
7. Singh AK. Incretin response in Asian type 2 diabetes: Are Indians different? Indian J Endocrinol Metab. 2015 Jan-Feb;19(1):30-8.
8. Singh AK et al. Evidence-Based Consensus on Positioning of SGLT2i in Type 2 Diabetes Mellitus in Indians. Diabetes Ther. 2019 Apr;10(2):393-428.
9. Kohei Kaku, Koichi Kisanuki, Mari Shibata, and Takashi Oohira, Benefit-Risk Assessment of Alogliptin for the Treatment of Type 2 Diabetes Mellitus Drug Saf. 2019; 42(11): 1311–1327.
10. Saini K, Sharma S, Khan Y. DPP-4 inhibitors for treating T2DM-hype or hope? an analysis based on the current literature. Frontiers in Molecular Biosciences. 2023 May 23;10:1130625.
11. Coppolino G, Leporini C, Rivoli L, Ursini F, di Paola ED, Cernaro V, Arturi F, Bolignano D, Russo E, De Sarro G, Andreucci M. Exploring the effects of DPP-4 inhibitors on the kidney from the bench to clinical trials. Pharmacological research. 2018 Mar 1;129:274-94.
Research & Reviews: A Journal of Pharmacology
| Volume | 14 |
| Issue | 02 |
| Received | June 10, 2024 |
| Accepted | July 12, 2024 |
| Published | July 15, 2024 |